Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II MyeloMATCH treatment trial compares ASTX727 with standard duration versus shorter duration of venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML). ASTX727 is a combination of decitabine and cedazuridine. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Shorter duration venetoclax may be as effective as standard duration venetoclax when given with ASTX727 for the treatment of newly diagnosed AML.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 60 lat w momencie rejestracji
- •Nowo rozpoznana, nietraktowana wcześniej ostra białaczka szpikowa (AML)
- •Co najmniej 20% złośliwych komórek w szpiku lub we krwi obwodowej
- •Uznana przez lekarza za niezdolna do intensywnego leczenia chemioterapią
- •Wcześniejsza rejestracja w studium MYELOMATCH
- •Liczba białych ciałek krwi poniżej określonej granicy przed rozpoczęciem leczenia
✗ Disqualifies
- •Ostra białaczka promptomielocijna typu APL
- •Mutacje genu FLT3
- •Mutacje genu TP53
- •Wcześniejsze leczenie białaczki (z pewnymi wyjątkami)
- •Jednoczesne uczestnictwo w innym badaniu klinicznym
Simplified criteria — AI translation
Trial details
- Minimum age
- 60 Years
- Last updated (source)
- October 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (40)
Kootenai Health - Coeur d'Alene
Coeur d'Alene, United States
Kootenai Clinic Cancer Services - Post Falls
Post Falls, United States
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, United States
Illinois CancerCare-Bloomington
Bloomington, United States
Illinois CancerCare-Canton
Canton, United States
Illinois CancerCare-Carthage
Carthage, United States
Cancer Care Specialists of Illinois - Decatur
Decatur, United States
Decatur Memorial Hospital
Decatur, United States
Illinois CancerCare-Eureka
Eureka, United States
Illinois CancerCare-Galesburg
Galesburg, United States
Illinois CancerCare-Kewanee Clinic
Kewanee, United States
Illinois CancerCare-Macomb
Macomb, United States
Illinois CancerCare-Ottawa Clinic
Ottawa, United States
Illinois CancerCare-Pekin
Pekin, United States
Illinois CancerCare-Peoria
Peoria, United States
Illinois CancerCare-Peru
Peru, United States
Illinois CancerCare-Princeton
Princeton, United States
Southern Illinois University School of Medicine
Springfield, United States
Springfield Clinic
Springfield, United States
Springfield Memorial Hospital
Springfield, United States
Illinois CancerCare - Washington
Washington, United States
University of Kentucky/Markey Cancer Center
Lexington, United States
LSU Health Baton Rouge-North Clinic
Baton Rouge, United States
Our Lady of the Lake Physician Group
Baton Rouge, United States
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton, United States
Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton, United States
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea, United States
Trinity Health Saint Mary Mercy Livonia Hospital
Livonia, United States
Trinity Health Saint Joseph Mercy Oakland Hospital
Pontiac, United States
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Ypsilanti, United States
Billings Clinic Cancer Center
Billings, United States
Benefis Sletten Cancer Institute
Great Falls, United States
Community Medical Center
Missoula, United States
Roswell Park Cancer Institute
Buffalo, United States
Ohio State University Comprehensive Cancer Center
Columbus, United States
University of Oklahoma Health Sciences Center
Oklahoma City, United States
Thomas Jefferson University Hospital
Philadelphia, United States
Gundersen Lutheran Medical Center
La Crosse, United States
Centro Comprensivo de Cancer de UPR
San Juan, Puerto Rico
San Juan City Hospital
San Juan, Puerto Rico
Trial contact
Site Public Contact
John M. Schallenkamp
PRINCIPAL_INVESTIGATOR
Site Public Contact
Bryan A. Faller
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Site Public Contact
Fevzi Yalniz
PRINCIPAL_INVESTIGATOR
Site Public Contact
Harry G. Sequeira Gross
PRINCIPAL_INVESTIGATOR
Site Public Contact
Tareq Al baghdadi
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Eunice S. Wang
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jayanshu Jain
PRINCIPAL_INVESTIGATOR
Site Public Contact
Manu Pandey
PRINCIPAL_INVESTIGATOR
Site Public Contact
Chetan S. Jeurkar
PRINCIPAL_INVESTIGATOR
Site Public Contact
David E. Marinier
PRINCIPAL_INVESTIGATOR
Site Public Contact
Luis J. Santos Reyes
PRINCIPAL_INVESTIGATOR
Site Public Contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.